Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M)
Form 10-Q / 10-K Restructuring Footnote
Latest, Q4 2023
211
Period ended Dec 31, 2023
Change on a year earlier
–
History
4 quarters
Since Q1 2023
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 211 | – | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 199 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 236 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Mar 31, 2023 | 97 | – | Form 10-Q (filed 2024-05-03) ↗ |
Breakdown
What makes up 2019 restructuring program (legacy) — total period charges incurred ($m)
- 2019 Restructuring Program (legacy) — Ending Accrual Reserve Balance ($M)597 · Q4 2023
- 2019 Restructuring Program (legacy) — Recorded in Cost of Sales ($M)55 · Q4 2023
- 2019 Restructuring Program (legacy) — Recorded in R&D ($M)0 · Q4 2023
- 2019 Restructuring Program (legacy) — Recorded in Restructuring Line Item ($M)127 · Q4 2023
Cite this data
StockData. (2026). Merck 2019 Restructuring Program (legacy) — Total Period Charges Incurred ($M) ($M), quarterly Q1 2023–Q4 2023 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/restr_program2019_incurred
See every metric in the Merck KPI table. Data updated Oct 26, 2026.